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Abstract 36 
PTK6/Brk is a non-receptor tyrosine kinase over-expressed in cancer. Here we demonstrate 37 
that cytosolic PTK6 is rapidly and robustly induced in response to hypoxic conditions in a 38 
HIF-1 independent manner. Furthermore, a proportion of hypoxic PTK6 subsequently re-39 
localised to the cell membrane. We observed that the rapid stabilisation of PTK6 is associated 40 
with a decrease in PTK6 ubiquitylation and we have identified c-Cbl as a putative PTK6 E3 41 
ligase in normoxia. The consequences of hypoxia-induced PTK6 stabilisation and subcellular 42 
re-localisation to the plasma membrane include increased cell motility and invasion, 43 
suggesting PTK6 targeting as a therapeutic approach to reduce hypoxia-regulated metastatic 44 
potential. This could have particular significance for breast cancer patients with triple 45 
negative disease. 46 
  47 
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INTRODUCTION 48 
PTK6 (Protein Tyrosine Kinase 6) or Brk (Breast tumour Kinase) is a cytoplasmic non-49 
receptor tyrosine kinase which has been shown to be highly expressed in various tumour 50 
types including breast carcinomas (85% of samples), as well as colorectal, prostate, lung, 51 
head and neck carcinomas and B- and T-lymphomas. 1-6 In normal tissues, PTK6 expression 52 
is restricted to the differentiated epithelium of the skin and gut, whilst in tumours the highest 53 
levels of PTK6 expression correlate with higher tumour grade, larger size, metastasis and 54 
consequently a poorer prognosis. 7-9  55 
PTK6 has specific functions in different tissue types, including regulating differentiation in 56 
normal tissues and promoting proliferation and cell survival in tumours, brought about by 57 
variations in cellular localisation. 1, 10 PTK6 is activated by a number of different ligands, as 58 
well as displaying a small amount of basal auto-phosphorylation in in vitro kinase assays. 11 59 
EGF (epidermal growth factor) and IGF (Insulin-like Growth Factor) induced signalling have 60 
been shown to activate PTK6 9, 12, 13, as have HGF (Hepatocyte Growth Factor) and 61 
osteopontin (OPN). 11, 14 Radiation treatment has also been reported to lead to the induction 62 
of PTK6 in both mouse intestine epithelial cells and human colorectal cancer cells, however, 63 
little is known about the mechanisms that regulate the de novo expression of Brk in tumours. 64 
15, 16 65 
The importance of the microenvironment, particularly hypoxia, for tumour establishment and 66 
metastasis is well characterised. 17 Tumour hypoxia arises as a consequence of high metabolic 67 
demand for oxygen caused by rapid tumour growth and the inefficiency of the tumour 68 
vasculature. 18 Many studies have shown that tumour hypoxia is significant as hypoxic 69 
tumours are associated with increased invasion, metastasis, poor patient survival and 70 
increased resistance to therapy. 19, 20 One of the key regulators of the hypoxic response is the 71 
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hypoxia-inducible transcription factor 1 (HIF1). Hypoxia-inducible genes regulate many 72 
biological processes including cell proliferation, angiogenesis, metabolism, apoptosis, 73 
immortalisation and migration. 21 Exposure to hypoxic conditions was recently shown to 74 
induce PTK6 in a HIF dependent manner in breast cancer cell lines. 22 However, PTK6 has 75 
not previously been identified as a HIF target, since no HIF binding to PTK6 promoter was 76 
identified in larger genome-wide ChIP-seq studies. 23, 24 This indicated that there might be 77 
other parallel mechanisms for hypoxia-mediated PTK6 induction.  78 
In this study, we showed that PTK6 was rapidly stabilised in hypoxic conditions in a post-79 
translational HIF1-independent manner in both breast and colorectal cancer cell lines. 80 
Specifically, we demonstrated that, in normoxic conditions PTK6 was targeted to the 81 
proteasome and that this process was inhibited in hypoxia. Hypoxia-mediated PTK6 82 
induction was associated with increased hypoxia-dependent migration and invasion. These 83 
findings are significant as they point to an additional mechanism of PTK6-induction by 84 
hypoxia in human cancers. 85 
 86 
87 
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RESULTS 88 
 89 
Hypoxia induces a rapid and robust stabilisation of PTK6 90 
Hypoxia is a know driver of many key aspects of tumour development. Recently, PTK6 has 91 
been shown to be hypoxia-inducible in triple negative breast cancer cell lines. 22 In order to 92 
confirm whether PTK6 is hypoxia-inducible in different cancer cell types, the hypoxia-93 
mediated induction of HIF1Į and PTK6 at both the mRNA and protein levels was examined 94 
in the MDA-MB-231 (breast) and RKO (colorectal) cell lines. When protein levels were 95 
examined, a rapid and robust induction of PTK6 at the protein level in both cell lines was 96 
observed, as early as 5 min after exposure to hypoxia (Figure 1A). PTK6 protein levels were 97 
induced in response to hypoxia prior to HIF1Į upregulation (Figure 1A) in contrast to 98 
previous studies. 22 In MDA-MB-231 cells, PTK6 mRNA increased after 18 h exposure to 99 
hypoxia, but not at earlier timepoints (6h), whereas no significant increase of PTK6 mRNA 100 
levels was observed for RKO cells (Figure 1B) at any of the time points studied. Due to the 101 
observed rapid PTK6 protein level induction kinetics in hypoxia, preceding HIF1Į induction, 102 
it could be questioned whether PTK6 could in turn affect HIF1Į stabilisation and/or activity. 103 
To address this, PTK6 was suppressed by RNA interference in RKO and MDA-MB-231 104 
cells, which were then exposed to hypoxia (2% O2). HIF-1Į induction in hypoxia was 105 
unaltered by the presence/absence of PTK6 (Figure S1A-B). Similarly, no effect of PTK6 106 
depletion was observed for the transcript levels of three well-characterised HIF-1 targets 107 
(Figure S1C), indicating that hypoxic PTK6 does not affect HIF stability and function. 108 
PTK6 is ubiquitylated in an oxygen-dependent manner  109 
Due to its rapid kinetics, it was plausible that the transcription-independent PTK6 protein 110 
stabilisation in hypoxia depicted in Figure 1 could occur via post-translational turnover in the 111 
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ubiquitin-proteasome system (UPS). In order to investigate this hypothesis, MDA-MB-231 112 
cells were exposed to proteasome inhibitors MG132, ALLN, Lactacystin, and Bortezomib for 113 
6 hours in normoxia (20% O2). Increased PTK6 levels were observed after treatment with 114 
these inhibitors, suggesting that, in normoxic conditions, PTK6 is actively degraded via the 115 
UPS (Figure 2A). To investigate the role of direct protein ubiquitylation in PTK6 stabilisation 116 
in hypoxia, constructs containing either tagged PTK6 (Flag-PTK6) and/or ubiquitin (HA-Ub) 117 
were transfected into HEK293T cells to ensure high levels of expression. The cells were then 118 
exposed to normoxia or hypoxia (2% O2) for 6 hours and Flag-PTK6 was 119 
immunoprecipitated (Figure 2B). Higher molecular weight forms of PTK6 were detected in 120 
normoxic conditions when both constructs were present. This suggested that, under these 121 
conditions, PTK6 was ubiquitylated. The presence of these higher molecular weight forms of 122 
PTK6 was decreased in hypoxic conditions, indicating that the level of PTK6 ubiquitylation 123 
was lower in hypoxia than in normoxic conditions (Figure 2B). These data imply that an E3 124 
ligase could control the level of PTK6 protein in an oxygen-dependent manner. The role of 125 
the known tyrosine kinase E3 ligase c-Cbl was investigated in this context. MDA-MB-231 126 
(breast) and RKO and HCT116 (colorectal) cell lines were transfected with c-Cbl siRNA. In 127 
MDA-MB-231 cells, suppression of c-Cbl led to a statistically significant increase in PTK6 128 
levels (Figure 2C, S2A). This effect was also evident (albeit not significant) to a lesser extent 129 
in the colorectal cell lines, including RKO (Figure 2C, S2A). To support this finding the 130 
levels of c-Cbl and PTK6 were determined in a range of cancer cell lines by Western blotting 131 
(Figure 2D). This analysis demonstrated a reciprocal relationship between the levels of PTK6 132 
and c-Cbl; that is, when one was relatively highly expressed the other was relatively low 133 
(Figure 2D-E, S2B). Altogether, these data support the hypothesis that PTK6 is ubiquitylated 134 
and degraded via the UPS in normoxic conditions and that this degradation is decreased in 135 
response to hypoxia, thereby allowing the protein to accumulate.  136 
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Hypoxia-induced PTK6 promotes cell motility and invasion  137 
The role of hypoxia in regulating the ability of cancer cells to disseminate and proliferate to 138 
secondary sites clearly contributes for the metastatic process. 25 Furthermore, PTK6 has been 139 
reported to regulate a number of processes that are central for cellular proliferation and 140 
metastatic spread, when associated with different membrane subcellular fractions. 26, 27 The 141 
subcellular localisation of normoxic and hypoxic PTK6 was investigated by biochemical and 142 
immunofluorescence approaches, where a clear increase in cytoplasmic hypoxic PTK6 was 143 
observed (Figure S3). Although most PTK6 protein in hypoxic MDA-MB-231 cells remained 144 
cytoplasmic, a fraction of it translocated to the cell membrane and co-localised with F-actin 145 
(Figure S3), indicating a potential role in cell motility under hypoxic conditions. In order to 146 
investigate this, scratch wound assays were performed in both MDA-MB-231 and RKO cells 147 
transfected with Scr (scramble) or PTK6 siRNA and exposed to hypoxic conditions (2% O2) 148 
(Figure 3A-B). Wound closure was significantly delayed in the absence of PTK6 in hypoxic 149 
conditions for both cell lines (Figure 3A-B). The xCELLigence real-time cell analyser 150 
(RTCA) system was used to allow real-time kinetic analysis of early motility events. This 151 
system allows the differentiation between early motility and proliferation events. 28. Real-152 
time hypoxic cell motility of MDA-MB-231 cells was decreased in the absence of PTK6 153 
(Figure 3C). Although PTK6 knockdown did not affect cell proliferation and clonogenic 154 
survival in hypoxia using 2D models (Figure S4), its potential role in 3D growth in hypoxic 155 
conditions was investigated using the mammosphere system. This allows the evaluation of 156 
the ability of breast cancer cells to survive and proliferate in an ECM-like substrate. Control 157 
Scr treated MDA-MB-231 cells formed larger mammospheres in hypoxic conditions (2% O2) 158 
when compared with normoxia (Figures 3D, S5). However, mammospheres were 159 
significantly smaller in the absence of PTK6 (Figure 3D), indicating a role for PTK6 in 160 
anchorage-independent 3D cell growth. Interestingly, mammospheres formed from the cells 161 
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lacking PTK6 were predominantly smooth, whereas PTK6-expressing mammospheres 162 
presented a spiky/invasive appearance (Figure 3E). This phenotype has been previously 163 
associated with increased invasive and tumorigenic ability. 29 The decreased invasive 164 
phenotype in the absence of PTK6 was further tested using conventional transwell assays, 165 
where both MDA-MB-231 and RKO cells had a lower invasive ability in the absence of 166 
PTK6 (Figures 3F, S6). This was reflected by an invasion index below 1 (0.46 for MDA-MB-167 
231 and 0.16 for RKO). These results indicate that PTK6 is important for hypoxia-mediated 168 
cellular motility and invasion, which are key factors in metastasis. 169 
PTK6 expression is linked to distant metastasis-free survival 170 
To determine whether our in vitro data suggesting that PTK6 expression is linked to 171 
metastatic potential correlated with findings in human tumours we examined the effects of 172 
PTK6 expression on distant metastasis-free survival (DMFS) in 1609 breast cancer patients 173 
using data from Györffy and colleagues (2010). 30 High Brk expression was correlated with a 174 
reduced metastasis-free survival (P=0.0017) (Figure 4A). 175 
Given our findings in the triple-negative breast cancer cell line, MDA-MB-231, we 176 
determined whether PTK6 expression was particularly linked with DMFS in the 220 patients 177 
from the Györffy data set with triple-negative (basal-like) breast tumours. The Kaplan Meier 178 
plot in Figure 4B shows that, as with the overall cohort, PTK6 expression is a poor prognostic 179 
indicator for DMFS in patients with basal-like breast cancer. Notably, there was a greater 180 
difference between the probabilities for basal-like breast cancers than was observed for the 181 
overall patient group. 182 
 183 
DISCUSSION 
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The role of hypoxia in tumour development and spread is well characterised. 17  However, 185 
although many key players in this process have been identified, many others remain 186 
uncharacterised. Tyner and co-workers identified hypoxia to be an inducer of the non-187 
receptor tyrosine kinase PTK6 in normal and neoplastic cells and that the induction was 188 
dependent on HIF1Į. 22 In our study we describe the rapid, post-translational induction of 189 
PTK6 protein levels in response to hypoxia in both breast and colorectal cancer cell lines 190 
(Figure 1) in a much shorter time frame than previously reported. 22 PTK6 induction occurred 191 
prior to HIF1Į stabilisation, implying that there is an additional HIF-independent mechanism 192 
mediating PTK6 protein level increase in hypoxic conditions. We did observe an increase of 193 
PTK6 mRNA after prolonged exposures to hypoxia for the breast cancer cell line MDA-MB-194 
231, similarly to the published findings by Tyner and co-workers. 22 However, as we 195 
observed no PTK6 transcript upregulation on shorter exposures to hypoxia in this cell line 196 
model, our data suggest that PTK6 induction could initially be independent of mRNA 197 
expression in breast cancer cells. Importantly, there was no hypoxia-dependent transcriptional 198 
upregulation of PTK6 in the RKO colorectal cancer cell line model, indicating the hypoxia-199 
mediated transcriptional upregulation of PTK6 could be cancer type dependent. To confirm 200 
that PTK6 induction in hypoxia could be independent of HIF and transcriptional mechanisms 201 
we showed that, in response to hypoxia, proteasomal-mediated degradation of PTK6 is 202 
reduced and that this correlated with decreased ubiquitylation of PTK6 (Figure 2). A 203 
candidate-based approach was used to investigate the possible role of specific E3 ligases in 204 
PTK6 stabilisation. c-Cbl was prioritised as it is known to have substrates including both 205 
receptor and non-receptor tyrosine kinases. 31, 32 It appears that c-Cbl could, in part, be 206 
responsible for regulating PTK6 levels during early hypoxia, independently of HIF, although 207 
how c-Cbl is itself regulated in an oxygen-dependent manner to effect PTK6 levels is still 208 
unclear. Recently, PTK6 has been reported to promote the ubiquitylation and degradation of 209 
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c-Cbl through targeted phosphorylation, which raises the intriguing possibility that a 210 
reciprocal feedback loop exists between c-Cbl and PTK6. 33 Furthermore, other E3 ligases, 211 
namely CHIP (C terminus of Hsc70-interacting protein) and SOCS3 (suppressor of cytokine 212 
signalling 3) were recently reported to enhance the proteasomal degradation of PTK6. 34, 35 213 
These data add further support to our finding that PTK6 levels are regulated by the 214 
proteasome and the regulation of E3 ligases in hypoxia warrants further investigation. This 215 
study also demonstrates that hypoxic PTK6 has a role in regulating cellular invasion and 216 
migration (Figure 3). Importantly, this is associated with a relocalisation to the cell 217 
membrane, a process that is reported to be essential for PTK6’s role in oncogenesis. 36  218 
Finally we show in a large patient cohort (1609 samples) that high PTK6 expression is 219 
correlated with reduced metastasis-free survival (Figure 4A) across all tumour subtypes, 220 
supporting our previous findings that elevated PTK expression is associated with breast 221 
tumours that are either invasive, more likely to metastasise, as well as data from other studies 222 
using much smaller sample sizes (less than 300). 8, 9, 22, 37 Aubele and colleagues reported that 223 
high PLA signals, indicating a physical interaction between PTK6 and HER2, correlated with 224 
reduced metastasis-free survival, although their earlier findings in 193 invasive breast cancers 225 
suggest that PTK6 may be a positive prognostic indicator. 38 This discrepancy has been 226 
discussed elsewhere and does highlight the difference between expression at the mRNA level 227 
compared to protein-based studies. 8 228 
Additionally, given that the reduction in metastasis free survival with high PTK6 expression 229 
appeared to be more marked in the 220 patients with triple-negative or basal-like breast 230 
cancer (Figure 4B), it is possible that, in the absence of other prognostic factors such as 231 
HER2, ER and PR, PTK6 levels become more important in predicting prognosis. 232 
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It has been suggested that inhibition of PTK6 would be an effective therapeutic approach. 5, 27 233 
However, the lack of commercially available specific inhibitors has not allowed for further 234 
investigations. Our in vitro results in both breast and colorectal cell line models show that 235 
PTK6 induction in hypoxia can be regulated by HIF-independent mechanisms, such as post-236 
translational modifications. Combined with the findings in breast cancers, our data add to the 237 
wealth of information describing the role of hypoxia in driving cell motility and invasion, 238 
indicating that targeting of PTK6 through the development of pharmacological inhibitors 239 
could potentially be used to decrease tumour metastatic potential and that this may be of 240 
particular benefit to patients with basal-like/triple negative breast cancers.  241 
  242 
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MATERIALS AND METHODS 243 
Cell lines, hypoxia, drug treatment and siRNA transfections. MDA-MB-231, MDA-MB-244 
453, MDA-MB-468, MDA-MB-361, BT474, T47D, MCF-7 and SKBR3 (breast), RKO, 245 
HCT116 and DLD1 (colorectal) and RT112, VmCuB1, T24 and 253J (bladder) cancer cell 246 
lines were grown in DMEM or RPMI-1640 (Sigma, USA) with 10% FBS. HEK293T 247 
(kidney) cells were grown in DMEM/10% FBS. All cell lines were purchased from ATCC or 248 
ECCAC and routinely tested as negative for mycoplasma. Hypoxia treatments were carried 249 
out in an In vivo2 400 (Ruskinn, Bridgend, UK) or Heracell incubator (ThermoFisher, UK). 250 
For experiments at <0.1% O2, cells were plated in glass dishes and placed in a Bactron II 251 
anaerobic chamber (Shell labs, USA). MG132 (Sigma, USA), ALLN (Ac-LLnL-CHO, 252 
Sigma, USA), Lactacystin (Merck Millipore, USA) and Bortezomib (Selleck Chemicals, 253 
USA) stocks were prepared in dimethyl sulfoxide (DMSO, Sigma, USA). Cells were 254 
transfected with PTK6 siRNA (GGUGAUUUCUCGAGACAAC dTdT) 8 or scramble siRNA 255 
(Life Technologies, UK) using DharmaFECT1 (Thermo Scientific, UK). Knockdown was 256 
obtained after double transfection over 48h. Transfection with Flag-PTK6 and HA-Ub (gift 257 
from Jason Parsons) was done using PEI (Polyethylenimine, Polysciences, USA).  258 
Cell lysis and Western blotting. For whole cell extract (WCE) preparation, cells were lysed 259 
in UTB (9 M urea, 75 mM Tris-HCl pH 7.5 and 0.15 M ȕ-mercaptoethanol) and 260 
immunoblotted as previously described. 39 Antibodies used were PTK6 (ICR-100) 12, Hif1Į 261 
and GAPDH (BD Biosciences, USA), c-Cbl, EGFR and Į-tubulin (Cell Signaling 262 
Technology, USA), HA-tag (Abcam, UK) and ȕ-actin (Santa Cruz, USA). The Odyssey 263 
infrared imaging technology was used for protein detection (LI-COR Biosciences, USA). 264 
Densitometry was done using ImageJ software (NIH, USA). 265 
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Immunoprecipitation (IP). Cells were lysed in IP lysis buffer: 150 mM NaCl, 20 mM Hepes 266 
pH 7.5, 0.5 mM EDTA, 0.5% NP40, 1X Complete protease inhibitor cocktail and 1X 267 
PhosStop phosphatase inhibitor cocktail (Roche, UK). Flag-PTK6 was immunoprecipitated 268 
using Flag-M2 agarose (Sigma, USA).  269 
Quantitative real time PCR. Quantitative real time PCR (qRT-PCR) was performed using 270 
Thermo Scientific Verso™ QRT-PCR (Thermo Scientific, UK) as previously described. 40, 41 271 
The qPCR reaction was carried out using the 7500 Fast Real Time PCR System (Life 272 
Technologies, UK). PTK6 and GLUT-1 expression levels were normalised to 18S rRNA. 273 
Primer sequences are available in the Supplementary Material (Table S1). 274 
Scratch wound assay and measurement of cellular invasion. Scratch wound assays were 275 
carried out as described previously. 42 For cellular invasion assays, cells were plated in 276 
control or Matrigel invasion chambers with 8 ȝm pore size (BD Biosciences, USA). Cells 277 
were allowed to invade for 18 h before fixing and staining with DAPI to visualise nuclei.  278 
Measurement of cellular proliferation and motility using the xCelligence system. 279 
Experiments were carried out using the xCelligence Real Time Cell Analyser (RTCA) DP 280 
instrument (Cambridge Biosciences, UK). Cell migration was assessed using 16-well CIM-281 
plates 16 as described. 28, 43 DMEM/10% FBS was added to the lower chamber as 282 
chemotractant and cells were seeded into the upper chamber at 40,000/well in serum free 283 
medium.  284 
Mammosphere formation assay. Matrigel (BD Biosciences, USA) diluted 1:1 in serum free 285 
medium was added to 24-well plates.  Cells were seeded at 2500 cells/well and allowed to 286 
adhere for 6h before exposure to hypoxia (2% O2). After 24 h cells were returned to normal 287 
culture conditions. Medium was changed every 2-3 days. After 10 days the mammospheres 288 
were imaged using an Eclipse SE2000-E microscope (Nikon, UK). Images were analysed 289 
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using ImageJ software (NIH, USA). At least 150 mammospheres were measured per 290 
condition. 291 
Breast cancer patient distant metastasis-free survival analysis. Kaplan-Meier curves for 292 
distant metastasis-free survival (DMFS) were generated using the KM-plotter on-line tool, 293 
(http://kmplot.com/analysis), which used microarray data for over 20,000 genes for 1609 294 
breast cancer patients.30 Analysis of PTK6 expression (Affymetrix ID 206482_at) was 295 
performed for 1609 breast cancer patient samples and a subset of 220 triple negative (basal-296 
like) breast cancer patients. Both analyses were performed regardless of lymph node status. 297 
Patients were grouped as having high or low PTK6 expression, and median expression was 298 
used as the cut-off. 299 
Statistical analysis. Statistical significance was determined using Student’s t-test and error 300 
bars represent +/- SEM.  301 
  302 
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FIGURE LEGENDS 417 
Figure 1. Hypoxia induces the rapid stabilisation of PTK6 418 
(A) RKO colorectal and MDA-MB-231 breast cancer cells were exposed to hypoxia (2% O2) 419 
for the periods indicated. Cells were lysed and PTK6 and HIF1Į levels were determined by 420 
western blotting. (B) RKO and MDA-MB-231 cells were exposed to hypoxia (2% O2) for the 421 
periods indicated. PTK6 and GLUT-1 expression levels were determined by qRT-PCR.  422 
 423 
Figure 2. PTK6 is ubiquitylated in an oxygen-dependent manner 424 
(A) MDA-MB-231 cells were treated for 6h with either vehicle (DMSO), 10 ȝM MG132, 50 425 
ȝM ALLN, 5 ȝM Lactacystin or 50 nM Bortezomib. PTK6 levels were determined by 426 
Western blotting. HIF1Į was used as a positive control for proteasomal inhibition in 427 
normoxic conditions and GAPDH as a loading control. (B) HEK293T cells were transfected 428 
with constructs expressing either Flag-PTK6, HA-Ub or both and exposed to normoxia 429 
(Norm) or Hypoxia 2% O2 (Hyp) for 6h in the presence of 10 ȝM MG132. Flag-PTK6 was 430 
immunoprecipitated (IP) and analysed by Western blotting for the presence of ubiquitinated 431 
PTK6 (indicated by arrows). Whole cell extracts (WCE) were analysed for the presence of 432 
PTK6 and GAPDH (loading control). Endogenous and ectopically expressed PTK6 in WCE 433 
are indicated as * and **, respectively. (C) MDA-MB-231 (breast), RKO and HCT116 434 
(colorectal) cells were transfected with either Scr (scramble) or c-Cbl siRNA for 72h. 435 
Western blotting was carried out to detect the endogenous levels of c-Cbl and PTK6. (D) 436 
Whole cell extracts were prepared from the breast, colorectal and bladder cancer cell lines 437 
indicated and Western blotting was performed for PTK6 and c-Cbl. Ǻ-actin was used as a 438 
loading control. (E) Histogram represents PTK6/c-Cbl ratios from panel in (D). 439 
Quantification values are depicted in Supplementary Figure S2B. (a.u.= arbitrary units of fold 440 
increase relative to ȕ-actin). 441 
 442 
Figure 3 Hypoxia-induced PTK6 promotes cell motility and invasion 443 
(A) MDA-MB-231 and RKO cells were treated with Scr (scramble) or PTK6 siRNA. Graph 444 
represents the percentage of wound closure after 18 h in 2% O2. Graphs represent the mean of 445 
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n=3 independent experiments.  (B) Representative images of scratch wound assays for (A). 446 
(C) MDA-MB-231 cells were treated with Scr or PTK6 siRNA. Kinetic real-time migration 447 
assays were performed at 3% O2 using the xCelligence Real Time Cell Analyser (RTCA) DP 448 
instrument. The graph depicts changes in the cell index (CI). Graph represents n=2 449 
experiments. (D) MDA-MB-231 cells were treated with Scr or PTK6 siRNA. Mammospheres 450 
were established and exposed to normoxia (Norm) or 2% O2 (Hyp) for 24 h. The graph 451 
represents a quantification of the average size of at least 150 mammospheres per condition. 452 
Data represent n=6 individual experiments. (E) MDA-MB-231 mammospheres were 453 
generated from cells transfected with Scr or PTK6 siRNA and treated as described in (D). 454 
Mammospheres were scored according to their morphological phenotype as non-invasive or 455 
invasive. Representative images of both phenotypes depicted in inset. Graph represents the 456 
percentage of different morphologies under each condition. Data represent n=6 individual 457 
experiments. (F) MDA-MB-231 and RKO cells were transfected with Scr or PTK6 siRNA as 458 
before. Cells were seeded in control (uncoated) or matrigel coated Transwell inserts with 8 459 
ȝm pore size and allowed to invade for 18h at 2% O2. Invasion index = % invasion PTK6 460 
siRNA/% invasion Scr. Results are representative of n=3 individual experiments. * p<0.05; 461 
** p<0.005; ***p<0.0001 462 
 463 
Figure 4. High PTK6 expression is associated with decreased distant metastasis-free 464 
survival in breast cancer patients 465 
(A-B) Kaplan-Meyer curves depicting the effect of PTK6 expression in distant metastasis-466 
free survival (DMFS) in 1609 breast cancer patients (A) and a subset of 220 triple negative 467 
(basal-like) patients (B). Kaplan-Meyer curves were generated using the KMplot online tool. 468 
Median expression was used as a cut-off for grouping into low (black) or high (grey) PTK6 469 
expression. HR – Hazard ratio 470 
 471 
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Figure S1. Hypoxic PTK6 does not affect HIF function 
 
(A-B) RKO (A) and MDA-MB-231 (B) cells were transfected with Scr or PTK6 siRNA 
and exposed to hypoxia (2% O2) at increasing times and harvested. PTK6, HIF1Į and 
GAPDH protein levels were detected by western blotting. (C) MDA-MB-231 cells were 
treated with Scr or PTK6 siRNA and exposed to hypoxia (2% O2) at increasing times and 
harvested. The levels of HIF1Į target genes GLUT1, ALDOA and BNIP3 were 
determined by qRT-PCR and normalized to 18S rRNA. Primer sequences available on 
Table S1. 
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S2: Quantification of the relative levels of PTK6 and c-Cbl  
(A) Extracts were prepared from the cancer cell lines indicated, treated or not with Scr or 
c-Cbl siRNA. Western blotting was performed for PTK6, c-Cbl and to ȕ-actin. (A) 
Histogram represents PTK6/ȕ-actin ratios from semi-quantitative analysis of PTK6 
protein levels regarding Scr or c-Cbl siRNA transfected MDA-MB-231, RKO and 
HCT116 cells (representative blot example in Figure 2C). Results are representative of 
n=3 individual experiments. * p<0.05 (B) Semi-quantitative analysis of Western blots in 
Figure 2D-E. (a.u.= arbitrary units of fold increase relative to ȕ-actin).
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Figure S3: Endogenous and ectopically expressed cytoplasmic PTK6 is induced by 
hypoxia and localizes to F-actin ruffles. 
 
(A) MDA-MB-231 cells were exposed to either normoxia (20% O2) or hypoxia (2% O2) 
for 18 h and harvested for biochemical fractionation. The various fractions and 
corresponding whole cell extracts were analysed by Western blotting for PTK6. EGFR 
and Į-tubulin were used as membrane fraction and cytosolic fraction markers, 
respectively. MDA-MB-231 cells were exposed to either normoxia or hypoxia (2% O2) 
for 18 h, fixed and stained for endogenous PTK6 (B) or transiently expressed Flag-tagged 
PTK6 (C). Staining was carried out as previously reported. 1 PTK6 was detected using 
anti-Brk antibody C19 (Santa Cruz, USA). TRITC-Phalloidin was used to stain for F-
actin. Cells were visualised using a 90i fluorescence microscope (Nikon).  
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Figure S4: PTK6 knockdown does not affect cell proliferation and viability in 
hypoxic conditions 
 
(A) MDA-MB-231 cells were transfected with either Scr (white) or PTK6 (black) siRNA. 
Kinetic real-time proliferation assays were performed at 3% O2. Briefly, cell proliferation 
was assessed using the xCelligence Real Time Cell Analyser (RTCA) DP instrument. 
Cells were seeded at 40,000/well in DMEM with 10% FBS in 16-well E-plates 16. The 
graph depicts changes in the cell index (CI). Graph represents n=2 experiments. (B) 
RKO, HCT116 and MDA-MB-231 cells were treated with Scr (white) or PTK6 (grey) 
siRNA and exposed to 24h of normoxia (Norm) or 2% O2 (Hyp). Colony survival assays 
were carried out. Briefly, cells were seeded into 6 well plates to obtain a minimum of 100 
colonies. After treatment colonies were allowed to form for 10-14 days. 
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Figure S5: Representative fields of the effect of the knockdown of PTK6 on MDA-
MB-231 mammosphere formation.  
 
MDA-MB-231 cells were transfected with scramble (scr) or PTK6 siRNA. Cells were 
then seeded in matrigel-coated wells and exposed to normoxia (Norm) or hypoxia 2% O2 
(Hyp) for 24 hours. After reoxygenation, cells were allowed to grow for 10 days. Bright 
field images were taken using a Nikon Eclipse SE2000-E microscope (4x objective) 
Scale bar = 200µm.  
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Figure S6: Representative fields of Transwell invasion assays 
 
MDA-MB-231 and RKO cells were treated with Scr or PTK6 siRNA. Cells were seeded 
in control of matrigel coated Transwell inserts and were allowed to invade for 18h at 2% 
O2. Figure represents examples of fields of view from experiments depicted in Figure 3-
F.   
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Table S1 – Sequence of primers used in this study 
 
Gene name Primer sequences 
PTK6 F: CTGCTCCGCGACTCTGATG 
R: GTAATTCTGCGACTCCAGGTAAC 
GLUT1 F: ATACTCATGACCATCGCGCTAG 
R: AAGAAGGCCACAAAGCCAAAG 
ALDOA F: GTTGTGGGCATCAAGGT  
R: CAATCTTCAGCACACAACG 
BNIP3 F: GGGTGTGGGTTATTTGTAAAGGC  
R: AAGGTAATGGTGGACAGCAAGG 
18S rRNA F: GCCCGAAGCGTTTACTTTGA 
R: TCCATTATTCCTAGCTGCGGTATC 
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